Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background Observational studies have suggested an increased risk of intracranial hemorrhage (ICH) associated with selective serotonin reuptake inhibitors (SSRIs) and other antidepressants primarily inhibiting serotonin reuptake. Objectives Our aim was to systematically review the available epidemiologic evidence regarding the risk of ICH associated with SSRIs and antidepressants inhibiting serotonin reuptake. Methods MEDLINE/PubMed and EMBASE were searched for all relevant articles in English, French, or German published before April 2017. Observational studies with SSRIs or any antidepressants classified by strength of serotonin reuptake inhibition as primary exposure, a comparison group, and ICH as outcome were eligible. Results Among twelve identified studies (six nested case-control, three cohort, two case-control, one case-crossover), seven assessed the risk of ICH associated with SSRIs (some also including other antidepressants primarily inhibiting serotonin reuptake), two the risk of ICH associated with inhibitors of serotonin reuptake according to the degree of reuptake inhibition, and three addressed both objectives. Four of ten studies showed an increased risk of ICH associated with SSRIs, with the two largest studies suggesting a moderate effect. Three of five studies showed an increased risk of ICH associated with strong inhibitors of serotonin reuptake. Limitations including residual confounding, inclusion of prevalent users, potentially inappropriate study desi…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The lack of broad scale studies may be attributed in part to the heterogeneity and complexity of the phenomenon itself, and the lack of standardized data publicly available5–6.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [6]
In the citing paper
“However, few machine-readable databases of ADEs exist, limiting our capacity to study drug safety on a broader, systematic scale.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [6]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“This systematic review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18], and following a prespecified protocol.”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“Screening of titles and abstracts for articles potentially eligible for further review was performed independently by two investigators (AD and CR) in accordance with the PRISMA checklist [19].”
MethodLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events
Maclure, M. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115853 · Cited by 2,327 · cited 1×
“Importantly, the study with the highest point estimate used a case-crossover design [17], which was developed for transient exposures and not for drugs often taken on a regular basis such as SSRIs [29].”
BackgroundOveradjustment bias and unnecessary adjustment in epidemiologic studies.
Schisterman, E. F., Cole, S. R., & Platt, R. W. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a819a1 · Cited by 2,096 · cited 1×
“Second, adjusting for covariates at cohort entry may become complicated, since some of these covariates could be affected by the drug itself and thus be in the causal pathway; such overadjustment has been shown to increase bias [33, 34].”
BackgroundEvaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 2×
“Second, adjusting for covariates at cohort entry may become complicated, since some of these covariates could be affected by the drug itself and thus be in the causal pathway; such overadjustment has been shown to increase bias [33, 34].”
BackgroundPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 2×
“Importantly, the strength of serotonin reuptake inhibition varies among different SSRIs and antidepressants in general [9].”
BackgroundLund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739 · cited 1×
“While the use of an active comparator has been suggested in order to decrease the impact of this bias and especially indication bias [30], only three studies compared SSRIs with other classes of antidepressants [15, 27], or compared strong with weak inhibitors of serotonin reuptake [13, 15].”
Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Leach, A. (1994) · Stroke · doi:10.1161/01.str.25.7.1342 · Cited by 714 · cited 1×
“Given the high fatality rate of ICH such as intracerebral and subarachnoid hemorrhage [10, 11] and the increasing use of antidepressants, including SSRIs, observed in the past decades [12], this potential association is of high clinical importance.”
BackgroundImmortal time bias in observational studies of drug effects
Suissa, S. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1357 · Cited by 584 · cited 2×
“We performed quality assessment considering aspects such as study design, exposure and outcome definition, statistical analysis, and classical biases, as well as methodological issues particular to pharmacoepidemiology such as inclusion of prevalent users or time-related biases [21, 22].”
BackgroundMethodIncidence and 10-Year Survival of Intracerebral Hemorrhage in a Population-Based Registry
Sacco, S., Marini, C., Toni, D., Olivieri, L., & Carolei, A. (2009) · Stroke · doi:10.1161/strokeaha.108.523209 · Cited by 553 · cited 1×
“Given the high fatality rate of ICH such as intracerebral and subarachnoid hemorrhage [10, 11] and the increasing use of antidepressants, including SSRIs, observed in the past decades [12], this potential association is of high clinical importance.”
BackgroundSMASH-U: A Proposal for Etiologic Classification of Intracerebral Hemorrhage
Meretoja, A., Strbian, D., Putaala, J., Curtze, S., Haapaniemi, E., Mustanoja, S., Sairanen, T., Satopää, J., Silvennoinen, H., Niemelä, M., et al. (2012) · Stroke · doi:10.1161/strokeaha.112.661603 · Cited by 342
Caceres, J. A., & Goldstein, J. N. (2012) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2012.06.003 · Cited by 328
Smoller, J. W. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.436 · Cited by 255 · cited 10×
“Several of the remaining studies either suffered from methodological shortcomings [17, 26, 28], or were underpowered to assess such effects [6, 23, 24], which could explain some inconsistencies between studies.”
BackgroundInfluentialInfluence of antidepressants on hemostasis
Halperin, D., & Reber, G. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.1/dhalperin · Cited by 242 · cited 1×
“In particular, SSRIs can inhibit the reuptake of serotonin into thrombocytes, and the depletion of serotonin is considered responsible for their antiplatelet action [8].”
BackgroundAnglin, R., Yuan, Y., Moayyedi, P., Tse, F., Armstrong, D., & Leontiadis, G. I. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.82 · Cited by 234 · cited 1×
“Although a moderate increase in the risk of gastrointestinal bleeding has been replicated in several observational studies and subsequent meta-analyses [2, 4], and can now be found in the summary of product characteristics of SSRIs [5], the findings on ICH have been contradictory [3, 6, 7].”
ResultSelective serotonin reuptake inhibitors and brain hemorrhage: A meta-analysis
Hackam, D. G., & Mrkobrada, M. (2012) · Neurology · doi:10.1212/wnl.0b013e318271f848 · Cited by 230
Jiang, H.-Y., Chen, H.-Z., Hu, X.-J., Yu, Z.-H., Yang, W., Deng, M., Zhang, Y.-H., & Ruan, B. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.06.021 · Cited by 213 · cited 2×
“Although a moderate increase in the risk of gastrointestinal bleeding has been replicated in several observational studies and subsequent meta-analyses [2, 4], and can now be found in the summary of product characteristics of SSRIs [5], the findings on ICH have been contradictory [3, 6, 7].”
BackgroundResultDaskalopoulou, M., George, J., Walters, K., Osborn, D. P., Batty, G. D., Stogiannis, D., Rapsomaniki, E., Pujades-Rodriguez, M., Denaxas, S., Udumyan, R., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153838 · Cited by 185 · cited 1×
“, depression) may be a risk factor for bleeding [15, 31].”
BackgroundBak, S., Tsiropoulos, I., Kjærsgaard, J. O., Andersen, M., Mellerup, E., Hallas, J., García Rodríguez, L. A., Christensen, K., & Gaist, D. (2002) · Stroke · doi:10.1161/01.str.0000018589.56991.ba · Cited by 140 · cited 9×
“Several of the remaining studies either suffered from methodological shortcomings [17, 26, 28], or were underpowered to assess such effects [6, 23, 24], which could explain some inconsistencies between studies.”
BackgroundResultInfluentialAssociation of Cerebrovascular Events With Antidepressant Use: A Case-Crossover Study
Wu, C.-S., Wang, S.-C., Cheng, Y.-C., & Gau, S. S.-F. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10071064 · Cited by 137
Renoux, C., Vahey, S., Dell’Aniello, S., & Boivin, J.-F. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4529 · Cited by 135 · cited 18×
“[15] Current use of SSRIs vs current use of TCAs 3036 cases RR 1.”
BackgroundResultInfluentialSelf-citationTime-window Bias in Case-control Studies: Statins and Lung Cancer
Suissa, S., Dell'Aniello, S., Vahey, S., & Renoux, C. (2011) · Epidemiology · doi:10.1097/ede.0b013e3182093a0f · Cited by 105 · cited 1×
“We performed quality assessment considering aspects such as study design, exposure and outcome definition, statistical analysis, and classical biases, as well as methodological issues particular to pharmacoepidemiology such as inclusion of prevalent users or time-related biases [21, 22].”
MethodSelf-citationIncrease in Antidepressant Medication in the US Adult Population between 1990 and 2003
Mojtabai, R. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112885 · Cited by 100
Intracranial haemorrhage and use of selective serotonin reuptake inhibitors
De Abajo, F. J., Jick, H., Derby, L., Jick, S., & Schmitz, S. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00216.x · Cited by 98 · cited 7×
“Several of the remaining studies either suffered from methodological shortcomings [17, 26, 28], or were underpowered to assess such effects [6, 23, 24], which could explain some inconsistencies between studies.”
BackgroundInfluentialShin, D., Oh, Y. H., Eom, C.-S., & Park, S. M. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7251-9 · Cited by 98 · cited 3×
“Previous systematic reviews or metaanalyses have focused mostly on the risk of ICH (or ICH subtypes) associated with SSRIs [3, 7].”
BackgroundResultSelective Serotonin Reuptake Inhibitors and Risk of Hemorrhagic Stroke
Kharofa, J., Sekar, P., Haverbusch, M., Moomaw, C., Flaherty, M., Kissela, B., Broderick, J., & Woo, D. (2007) · Stroke · doi:10.1161/strokeaha.107.491472 · Cited by 93 · cited 10×
“Several of the remaining studies either suffered from methodological shortcomings [17, 26, 28], or were underpowered to assess such effects [6, 23, 24], which could explain some inconsistencies between studies.”
BackgroundInfluentialChen, V., Guo, J. J., Li, H., Wulsin, L., & Patel, N. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k369 · Cited by 93 · cited 8×
“Several of the remaining studies either suffered from methodological shortcomings [17, 26, 28], or were underpowered to assess such effects [6, 23, 24], which could explain some inconsistencies between studies.”
BackgroundInfluentialSwenson, J. R., Doucette, S., & Fergusson, D. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605101408 · Cited by 72 · cited 2×
“The rarity of the event, the small sample size, and the incomplete reporting of adverse events in those RCTs probably account for this failure [36].”
BackgroundUse of Serotonergic Drugs and the Risk of Bleeding
Verdel, B. M., Souverein, P. C., Meenks, S. D., Heerdink, E. R., Leufkens, H. G. M., & Egberts, T. C. G. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.240 · Cited by 56 · cited 10×
“Among the five studies that addressed the risk of ICH associated with the strength of inhibition of serotonin reuptake, two were nested case-control studies [14, 15], one was a cohort study [13], one was a case-control study [16], and one was a case-crossover study [17].”
BackgroundResultInfluentialCastro, V. M., Gallagher, P. J., Clements, C. C., Murphy, S. N., Gainer, V. S., Fava, M., Weilburg, J. B., Churchill, S. E., Kohane, I. S., Iosifescu, D. V., et al. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000544 · Cited by 53 · cited 8×
“Among the five studies that addressed the risk of ICH associated with the strength of inhibition of serotonin reuptake, two were nested case-control studies [14, 15], one was a cohort study [13], one was a case-control study [16], and one was a case-crossover study [17].”
BackgroundResultInfluentialThe use of antidepressants and the risk of haemorrhagic stroke: a nested case control study
Douglas, I., Smeeth, L. L., & Irvine, D. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03797.x · Cited by 51 · cited 6×
“Three of the seven studies assessing the risk of ICH associated with the use of SSRIs also considered drugs that, while inhibiting serotonin reuptake to some extent, are not specifically classified as SSRIs (clomipramine [6, 24], trazodone [24], venlafaxine [25], mirtazapine [25], duloxetine [25]).”
BackgroundInfluentialPersistent User Bias in Case-Crossover Studies in Pharmacoepidemiology
Hallas, J., Pottegård, A., Wang, S. V., Schneeweiß, S., & Gagne, J. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kww079 · Cited by 48 · cited 1×
“Recently, it was shown that when implementing withinsubject designs, persistent drug use can lead to an upward bias in the effect estimates [32].”
BackgroundChen, Y., Guo, J. J., & Patel, N. C. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1699 · Cited by 33 · cited 9×
“Among the five studies that addressed the risk of ICH associated with the strength of inhibition of serotonin reuptake, two were nested case-control studies [14, 15], one was a cohort study [13], one was a case-control study [16], and one was a case-crossover study [17].”
BackgroundResultInfluentialLee, Y., Lin, C., Lin, M.-S., Lu, Y., Chang, C., & Lin, J. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09394 · Cited by 19 · cited 9×
“All were observational studies, consisting of six nested case-control studies [6, 14, 15, 23–25], three cohort studies [13, 27, 28], two case-control studies [16, 26], and one case-crossover study [17].”
BackgroundResultInfluential
Cited by
Greenberg, S. M., Ziai, W. C., Cordonnier, C., Dowlatshahi, D., Francis, B., Goldstein, J. N., Hemphill, J. C., Johnson, R., Keigher, K. M., Mack, W. J., et al. (2022) · Stroke · doi:10.1161/str.0000000000000407 · Cited by 1,639
Ziai, W., & Carhuapoma, J. R. (2018) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000672 · Cited by 170
Nochaiwong, S., Ruengorn, C., Awiphan, R., Chai‐Adisaksopha, C., Tantraworasin, A., Phosuya, C., Kanjanarat, P., Chongruksut, W., Sood, M. M., & Thavorn, K. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.2017474 · Cited by 97
Rahman, A. A., Platt, R. W., Beradid, S., Boivin, J., Rej, S., & Renoux, C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.3208 · Cited by 70
Self-citationClinically relevant drug interactions between newer antidepressants and oral anticoagulants
Spina, E., Barbieri, M. A., Cicala, G., Bruno, A., & de León, J. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1700952 · Cited by 46
Metadata
- Authors
- Douros, A., Ades, M., & Renoux, C.
- Affiliations
- Jewish General Hospital (CA)
- McGill University (CA)
- Corresponding author
- Renoux, Christel
- Venue
- CNS Drugs
- Published
- 2018-03-13
- Volume
- 32
- Issue
- 4
- Pages
- 321-334
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2791111957
- Cited by
- 42
- References
- 37
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 2
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- intracranial hemorrhage, selective serotonin reuptake inhibitors, antidepressants, serotonin reuptake inhibition, drug safety, adverse drug reactions
- MeSH terms
- Antidepressive Agents, Humans, Selective Serotonin Reuptake Inhibitors, Intracranial Hemorrhages
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.